A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis associated interstitial lung disease

Recruiting
99 years or below
All
Phase 3
1 Location

Brief description of study

Systemic sclerosis is a rare chronic autoimmune connective tissue disease. B cells have been reported to play a central role in the pathogenesis of SSc and B cell depletion has been shown to offer benefit to patients with SSc. Belimumab is a monoclonal antibody, which inhibits the survival of B cells. This study will assess whether treatment of SScILD patients with belimumab will result in the stabilization and/or improvement of lung function.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 27 Feb 2026. Study ID: 24-0065

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center